JTCC Researchers Play Important Role in New England Journal of Medicine Transplant StudyMon, November 19, 2012
John Theurer Cancer Center Researchers Play Important Role in New England Journal of Medicine Study that May Change How Transplant Physicians Practice
Phase 3 Study Finds No Significant Survival Difference Between Blood Stem Cells and Bone Marrow Transplants for Cancer Patients
Hackensack, NJ (November 19, 2012) – Researchers from John Theurer Cancer Center at Hackensack University Medical Center, one of the nation’s 50 best cancer centers, played an important role in a study published in the New England Journal of Medicine on October 18 that may change the current blood and marrow transplantation practices. The phase 3, multicenter study compared harvesting stem cells from bone marrow rather than blood and suggests there are benefits to both approaches, but no survival differences between the two methods.
Over the past 10 years, 75 percent of stem cell transplants from unrelated adult donors have used peripheral blood stem cells rather than those harvested from bone marrow without clinical data to support this shift. The study did not find significant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors.
“We did find that peripheral-blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduce the risk of developing chronic graft-versus-host disease (GVHD), a complication that is frequently debilitating,” said study author Scott Rowley, M.D., Chief, Blood and Marrow Transplantation at John Theurer Cancer Center.
GVHD is a common complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. This can cause a variety of serious side effects, such as skin rashes, liver problems and diarrhea. Chronic GVHD usually starts three months after transplant and can last a lifetime. Its symptoms may include chronic pain, dry eyes and mouth, fatigue, skin rash, weight loss.
“As one of the 10 largest blood and marrow transplant programs in the nation, we remain committed to being on the forefront of the latest transplantation research and treatment,” said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer and Professor and Vice President of Cancer Services, John Theurer Cancer Center.
To view the complete study, visit the New England Journal of Medicine online.
About John Theurer Cancer Center at Hackensack University Medical Center
John Theurer Cancer Center at Hackensack University is among the nation’s top 50 U.S. News and World Report Best Hospitals for cancer – the highest-ranked in New Jersey with this designation. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.
Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. The John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, access to clinical trials, compassionate care and medical expertise—all under one roof. For more information please visit jtcancercenter.org.